BIOMAE
BIOMAE provides biomonitoring tools to measure contamination and toxicity of aquatic environments. The company presents tools for measuring and monitoring the quality of aquatic environments from markers of effects on a pollutant invertebrate transplanted directly into the environment. The biomonitoring tools come from years of research, making it possible to analyze the bioavailability of the contaminants and the degree of toxicity, directly in the medium. The company operates a methodological breakthrough to identify the issue of diagnosis for environmental quality monitoring. BIOMAE was founded on 2014 and is based in Gaillard, France.
BIOMAE
Industry:
Aquaculture Biometrics Biotechnology Environmental Engineering Pollution Control
Founded:
2014-01-01
Address:
Gaillard, Rhone-Alpes, France
Country:
France
Website Url:
http://www.biomae.com
Total Employee:
1+
Status:
Active
Contact:
+04 74 61 17 42
Email Addresses:
[email protected]
Total Funding:
850 K EUR
Technology used in webpage:
IPv6 Google Maps 1and1
Current Employees Featured
Founder
Investors List
Pertinence Invest
Pertinence Invest investment in Seed Round - BIOMAE
Rhone-Alpes Creation
Rhone-Alpes Creation investment in Seed Round - BIOMAE
Alps Capital innovation
Alps Capital innovation investment in Seed Round - BIOMAE
Official Site Inspections
http://www.biomae.com
- Host name: 217-160-0-110.elastic-ssl.ui-r.com
- IP address: 217.160.0.110
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "BIOMAE"
Biomea Fusion - Crunchbase Company Profile & Funding
Biomea Fusion is a privately held precision medicine company with a mission to revolutionize drug development to create more effective therapies for cancer patients. Biomea Fusion has a development portfolio that targets specific gene โฆSee details»
QUICK FACTS โ Biomea Corporate Overview and Programs
Biomea Fusion (NASDAQ: BMEA) 900 Middlefield Rd 4th Floor, Redwood City, CA 94063 www.biomeafusion.com . Our Programs . We believe that covalent small molecules have the โฆSee details»
QUICK FACTS Biomea Corporate Overview and Programs - Biomea โฆ
Biomea Fusion (NASDAQ: BMEA) 900 Middlefield Rd 4th Floor, Redwood City, CA 94063 www.biomeafusion.com Our Programs We believe that covalent small molecules have the โฆSee details»
Investors & Media | Biomea Fusion
Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic disease and โฆSee details»
Biomea Fusion, Inc. (BMEA) Company Profile & Facts - Yahoo โฆ
See the company profile for Biomea Fusion, Inc. (BMEA) including business summary, industry/sector information, number of employees, business summary, corporate governance, โฆSee details»
Leadership - Biomea Fusion
At Biomea, Heow is the Chief Technical & Quality Officer and is responsible for all aspects of CMC development, manufacturing, supply chain and Quality Operations. ... Dr. Pettus has โฆSee details»
Biomea Fusion, Inc. (BMEA) Company Profile & Overview - Stock โฆ
Apr 16, 2021 Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically โฆSee details»
Biomea Fusion, Inc. (BMEA) - Yahoo Finance Canada
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined โฆSee details»
biomea fusion - Org Chart, Teams, Culture & Jobs - The Org
Biomea Fusion, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined โฆSee details»
Biomea Fusion - Contacts, Employees, Board Members
Organization. Biomea Fusion . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Profiles 1. Contacts 64. About. Biomea โฆSee details»
Biomea Fusion, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Biomea Fusion, Inc. with its drug pipeline, therapeutic area, technology platform, 5 clinical trials, 92 news, and 14 literature, Disease Domain:Neoplasms, Endocrinology and Metabolic โฆSee details»
BMEA Corporate Presentation
Biomea - Icovamenib Novel Irreversible Covalent Menin Inhibitor Protein Binding Data icovamenib K d (nM) <1.0 x 10-12 Targetable Cysteine Binding Selectivity CYS1 100% CYS2 0% CYS3 โฆSee details»
Biomea Fusion Reports Third Quarter 2024 Financial Results and
Oct 29, 2024 --Biomea Fusion, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with โฆSee details»
Biomea Fusion Inc (BMEA-Q) Stock Price and News
Real-time Price Updates for Biomea Fusion Inc (BMEA-Q), along with buy or sell indicators, analysis, charts, historical performance, news and moreSee details»
Pipeline - Biomea Fusion
In March 2023, Biomea reported initial clinical data from the first two cohorts of the Phase II portion of COVALENT-111 (NCT05731544). As reported, 89% of patients enrolled in Cohort 3 โฆSee details»
Biomea Fusion Announces Approval of โicovamenibโ as ... - BioSpace
Oct 22, 2024 REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (โBiomeaโ) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to โฆSee details»
Quick Facts - Biomea Overview Icov NoNav - Biomea Fusion
Prior to founding Biomea Fusion in 2017, Ramses and Tom built-up Point Sur Investors, a long-only biotech investment fund focused solely on innovative therapies that signi๏ฌcantly improve โฆSee details»
BIOMAE Company Profile - Office Locations, Competitors, โฆ
BIOMAE $899.27 k in total funding,. See insights on BIOMAE including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Biomea Fusion Announces Approval of icovamenib as International ...
Biomea Fusion Announces Approval of icovamenib as International Nonproprietary Name for BMF-219 October 21, 2024 ... genetically defined cancers, today announced that the World โฆSee details»
BMF-650 - Drug Targets, Indications, Patents - Synapse
6 days ago The increase is offset by the decrease in insurance and facilities related expenses of $0.5 million. About Biomea Fusion Biomea Fusion is a clinical-stage biopharmaceutical โฆSee details»